We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Chemical Test Refined to Detect Tainted Heparin

By LabMedica International staff writers
Posted on 11 Oct 2011
A rapid test has been devised that will detect adulterated heparin, a blood thinner taken by millions of people worldwide each year to prevent blood clots.

The test can quickly and economically detect adulterants, including the substance responsible for hundreds of illnesses and deaths among patients taking heparin in 2008 that had to be recalled. More...


Scientists from the US Food and Drug Administration (Silver Spring, MD, USA) identified the culprit, a substance called over-sulfated chondroitin sulfate (OSCS). They developed a 96-well plate format assay for sensitive detection of OSCS in heparin active pharmaceutical ingredient (API) and crude heparin based on Leclerc polythiophene polymer (LPTP) and heparinase digestion of heparin. OSCS is a synthetic dietary supplement derived from chondroitin sulfate type A that some people take to treat osteoarthritis. Scientists concluded that OSCS, which is inexpensive, had been intentionally added to heparin as a so-called “economically motivated adulterant” (EMA), to boost profits. Current tests to detect EMAs in heparin are difficult to perform and must be done in laboratories.

To overcome these challenges, the investigators developed a simple color test in which normal heparin samples turn red in color, but OSCS contaminated samples do not change color. In the present study, they wanted to know whether their test could detect additional EMAs. They found that the test could detect several other possible EMAs, such as those that could be made by over-sulfation of waste products formed during heparin production. The colorimetric microplate LPTP/heparinase test detected OSCS in heparin sodium API by the naked eye down to the 0.1% level and in crude heparin down to the 0.1% level with a plate reader.

The investigators concluded on the basis of their results, a portable test to detect even tiny amounts of different EMAs could be developed to insure the safety of the heparin supply chain. Like heparin, OSCS also prevents blood from forming dangerous clots, but unlike heparin, OSCS can trigger potentially fatal anaphylactic reactions in sensitive individuals. The study was published on August 5, 2011, in the journal Analytical Chemistry.

Related Links:

US Food and Drug Administration



New
Gold Member
Automatic Hematology Analyzer
CF9600
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Automated Urinalysis Solution
UN-9000
New
Clinical Informatics Platform
CLARION™
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.